Category: Assay Development and Screening

1157-C - Development of a fluorescent NFS1 Assay.

Tuesday, February 6, 2018
2:00 PM - 3:00 PM

NFS1 is a cysteine desulphurase required for the assembly of iron-sulphur clusters (FeS) and intracellular iron homeostasis. FeS are essential prosthetic groups involved in catalysis, protein folding/stability, and sulphur donating enzymes.


Several critical pathways in cancer cells are dependent on intact FeS cluster assembly including haem biosynthesis, energy production, DNA replication and repair, ribosomal recycling and fatty-acid biosynthesis.


NFS1 RNAi leads to loss of activity of several key iron-sulphur  enzymes, morphological changes of mitochondria and growth inhibition of cultured tumour cells.


Current  NFS1 assays (including ELISA; methylene blue; circular dichroism; alanine or 55Fe or sulphur quantification) are not suited to support Drug Discovery.


Here we present the development of a robust fluorescent NFS1 assay suitable for HTS. 

Paul Hales

Sr. Scientist I
Takeda Pharmaceuticals Inc
Cambridge, MA

Member of Takeda Boston's Lead Discovery Group. Responsible for assay development and HTS/HTL.